Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients

• DOI: 10.1111/resp.14894
• Publication Date: 2025-02-11T00:20:47Z
• Authors: Roger M. Li; Dino B. A. Tan; Chantalia Tedja; Wendy A. Cooper; Helen E. Jo; Christopher Grainge; Ian N. Glaspole; Nicole Goh; Samantha Ellis; Peter M. A. Hopkins; Christopher Zappala; Gregory J. Keir; Paul N. Reynolds; Sally Chapman; E. Haydn Walters; Darryl Knight; Svetlana Baltic; HuiJun Chih; Tamera J. Corte; Yuben P. Moodley
• Keywords: DLCO

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor prognosis. Antifibrotics slow the decline of function after 12-months, but limited studies have examined role circulatory biomarkers in antifibrotic treated IPF patients. Serum from 98 participants, Australian Pulmonary Fibrosis Registry were collected at four time-points over 1 year post-antifibrotic treatment and analysed as two separate cohorts. Patients stratified progressive, if they experienced ≥ 10% FVC or 15% DLCO deceased within initiation: otherwise stable. Ten molecules interest measured by ELISAs patient serum. Baseline MMP7 levels higher than stable patients Cohort (p = 0.02) 2 0.0002). also best differentiated (Cohort 1, AUC 0.74, p 0.02; 2, 0.81, 0.0003). Regression analysis combined cohort showed that elevated predicted 12-month progression (OR 1.530, 0.010) increased risk overall mortality (HR 1.268, 0.002). LASSO regression identified multi-biomarker panel (MMP7, ICAM-1, CHI3L1, CA125) more accurately alone. Furthermore, GAP MMP7, CCL18 SP-D was predictive 3-year along can predict mortality, potential for optimising management.